Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Pablo Lee"'
Publikováno v:
Journal of Cancer
Introduction: With a gap in a full understanding of the mechanisms by which survival is extended for patients with cancer who are treated with novel biologic and targeted agents, there is the risk that discordant progression-free and overall survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e34eaa9c668046ef8b8037fc1a17134d
http://europepmc.org/articles/PMC6636299
http://europepmc.org/articles/PMC6636299
Autor:
Jin-Yuan Shih, Katherine B. Winfree, Frances A. Shepherd, Rebecca Cheng, Martin Reck, Pablo Lee, R. Varea, Andreas Sashegyi, Mark A. Socinski, Marina Chiara Garassino, Martina Imbimbo, Anne Tsao, Benjamin Levy, Edward B. Garon
Publikováno v:
Lung Cancer. 120:62-69
A majority of patients with advanced or metastatic non-small cell lung cancer (NSCLC) will experience disease progression after first-line therapy. Patients who have advanced NSCLC that is especially aggressive, which is defined as disease that rapid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeff1c49c12cd85c2942a5a8a31a2fe7
https://doi.org/10.1016/j.lungcan.2018.03.025
https://doi.org/10.1016/j.lungcan.2018.03.025
Autor:
Martin Reck, Ernest Nadal, Pablo Lee, Joseph Treat, Edward B. Garon, O Juan, Kazuhiko Nakagawa, S. He, Jingyi Liu, Rita P. Dalal
Publikováno v:
Pneumologie. 71:S1-S125
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::476b15e4c6e3aeed077afc370ce7b58a
https://doi.org/10.1055/s-0037-1598342
https://doi.org/10.1055/s-0037-1598342
Autor:
Edward B. Garon, M Kimmich, Annamaria Zimmermann, Ekaterine Alexandris, Martin Reck, M Perol, W. Schütte, C. Schumann, Pablo Lee
Publikováno v:
Pneumologie. 71:S1-S125
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa9204782aa972352943f03a7865b607
https://doi.org/10.1055/s-0037-1598331
https://doi.org/10.1055/s-0037-1598331
Autor:
Victoria Soldatenkova, K. Park, Viola W. Zhu, C. McCoach, L. Potter, D.S.W. Tan, Koichi Goto, Jennifer Kherani, Christian D. Rolfo, E. Olek, Benjamin Besse, S. Farajian, Pablo Lee
Publikováno v:
Annals of Oncology. 31:S835-S836
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4a0877612574cf89dfaef87b87e1d51
https://doi.org/10.1016/j.annonc.2020.08.1605
https://doi.org/10.1016/j.annonc.2020.08.1605
Autor:
Katharina Wolff, Gebra Cuyun Carter, Pablo Lee, Joo Hang Kim, Martin Reck, Lara Iglesias Docampo, Haralabos P. Kalofonos, S. V. Orlov, Giorgio V. Scagliotti, Steven Gans, Ekaterine Alexandris, Odd Terje Brustugun, Ana B Oton, Annamaria Zimmermann, Maurice Pérol, Michael Thomas, Mark A. Socinski, Oliver Gautschi, Victoria Jennifer Stefaniak, Edward B. Garon
Publikováno v:
ESMO Open
Introduction Non-small-cell lung cancer (NSCLC) is a heterogeneous disease. Front-line therapy may affect responses to subsequent treatment regimens, thus influencing second-line therapy decision making. In the randomised phase 3 REVEL study, second-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30ffc28de67ed5912575275f12141e97
https://pubmed.ncbi.nlm.nih.gov/31958290
https://pubmed.ncbi.nlm.nih.gov/31958290
Autor:
Samuel Cowan Ramage, Scott S. Barker, Volker Wacheck, Ashwin Shahir, Emily Barrett, William D. Tap, Steven Attia, Brian A. Van Tine, Rangaswamy Govindarajan, Neeta Somaiah, Pablo Lee
Publikováno v:
Journal of oncology practice. 15(11)
PURPOSE: Olaratumab is a human monoclonal immunoglobulin G1 antibody against platelet-derived growth factor receptor-α. We report the nature and frequency of infusion-related reactions (IRRs) with olaratumab in clinical trials and postmarketing repo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d691d87b65bdf8eb10a7e6a151eb0f
https://pubmed.ncbi.nlm.nih.gov/31693451
https://pubmed.ncbi.nlm.nih.gov/31693451
Autor:
Tricia Alleyne, Maria T. Camacho, Chinyere Onyearugbulem, Fares Kokash, Bibek Bista, Luis Pablo Lee, Enrique Caceres
Publikováno v:
Critical Care Medicine. 49:316-316
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5aade59bb21de6586abeca3bfe843c80
https://doi.org/10.1097/01.ccm.0000728460.14685.1e
https://doi.org/10.1097/01.ccm.0000728460.14685.1e
Autor:
Keunchil Park, Jin Hyoung Kang, Pablo Lee, Annamaria Zimmermann, Eun Kyung Cho, Tarun Puri, Mauro Orlando, Joo Hang Kim, Ekaterine Alexandris, Jin-Yuan Shih
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose REVEL demonstrated improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with docetaxel+ramucirumab versus docetaxel+placebo in 1,253 intent-to-treat (ITT) stage IV non-small cell lung cancer patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c84c80228db8001daa9f1144b4916c1
https://doi.org/10.4143/crt.2015.401
https://doi.org/10.4143/crt.2015.401
Autor:
David Ferry, Sotaro Enatsu, Toshiko Koue, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kiyotaka Yoh, Takashi Nakamura, Yuichiro Ohe, Pablo Lee, Makoto Nishio, Kazuo Kasahara, Yukio Hosomi, Toshiaki Takahashi, Tomohide Tamura, Kazuhiko Yamada
Publikováno v:
Lung Cancer. 99:186-193
Objectives Ramucirumab plus docetaxel prolongs survival in patients with non-small cell lung cancer (NSCLC) with disease progression after platinum-based therapy. This phase II, double-blind, randomized, placebo-controlled study assessed efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3e97c0dd27ceb984e54f305e620e7fe
https://doi.org/10.1016/j.lungcan.2016.07.019
https://doi.org/10.1016/j.lungcan.2016.07.019